OliX Pharmaceuticals, Inc

226950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩110,300-3.50%

2026-09-18

Financials

Valuation Metrics

OliX Pharmaceuticals, Inc's Market Cap is ₩2.5T. At end of 2025 it was ₩3.2T. Ranked #178 of 2,421 in KR market (top 7%), #33 of 1,640 on KOSDAQ (top 2%), #15 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	2.51T KRW	KR#178/2,421 Sec#15/231
Revenue	13.64B KRW	KR#2,235/2,421 Sec#168/231
Net Income	-14.03B KRW	KR—/2,421 Sec—/231
Total Assets	274.07B KRW	KR#1,088/2,421 Sec#74/231
Net Assets	237.42B KRW	KR#853/2,421 Sec#56/231
Employees	69	KR#1,887/2,421 Sec#163/231
Value
P/B	10.57x	KR#2,361/2,421 Sec#211/231
P/S	184.03x	KR#2,400/2,421 Sec#217/231
Profitability
ROE	-5.91%	KR#1,828/2,421 Sec#132/231
ROA	-5.12%	KR#1,937/2,421 Sec#138/231
Op. Margin	-304.72%	KR#2,349/2,421 Sec#194/231
Revenue Growth	80.93%	KR#115/2,421 Sec#19/231
Financial Health
Debt Ratio	15.43%	KR#260/2,421 Sec#39/231
Total Debt	19.64B KRW	KR#1,386/2,421 Sec#109/231
Cash	111.48B KRW	KR#433/2,421 Sec#20/231
Current Ratio	11.74x	KR#80/2,421 Sec#19/231
Performance
1Y Return	30.53%	KR#364/2,421 Sec#20/231
1M Return	5.65%	KR#707/2,421 Sec#49/231
From 52W High	-49.17%	KR#1,357/2,421 Sec#103/231
1Y MDD	-56.76%	KR#1,299/2,421 Sec#105/231
Trading
Volume	147,727 shares	KR#600/2,421 Sec#49/231
Trading Value	16.50B KRW	KR#187/2,421 Sec#12/231
Foreign Own.	10.87%	KR#446/2,421 Sec#38/231
Per Share
EPS	-617 KRW	KR—/2,421 Sec—/231
BPS	10,436 KRW	KR#962/2,421 Sec#66/231

Company Info

CEO 이동기

Employees 69

Founded 2010

HQ 경기도 성남시, KR

Website www.olixpharma.com

동사는 RNA간섭 플랫폼 기반 신약개발 기업으로, 자가전달 비대칭 siRNA 원천기술을 보유하여 아시아 최초로 임상에 진입함. 모든 유전자 표적이 가능하고 후보물질 선정 기간을 1년 이내로 단축할 수 있음. 비대칭 siRNA 구조로 오프타겟 효과 및 면역 반응을 최소화하고 GalNAc-asiRNA 플랫폼으로 간 세포 전달 효율을 높여 글로벌 기술 경쟁력을 확보하고 있음. 올릭스는 2010년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.